Osmotica Pharmaceuticals plc (OSMT) and Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) Comparing side by side

Osmotica Pharmaceuticals plc (NASDAQ:OSMT) and Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) compete against each other in the Biotechnology sector. We will compare them and contrast their analyst recommendations, institutional ownership, profitability, risk, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Osmotica Pharmaceuticals plc 274.34M 1.50 6.40M -0.13 0.00
Rocket Pharmaceuticals Inc. N/A 0.00 53.85M -1.94 0.00

Table 1 demonstrates Osmotica Pharmaceuticals plc and Rocket Pharmaceuticals Inc.’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 demonstrates the return on assets, net margins and return on equity of Osmotica Pharmaceuticals plc and Rocket Pharmaceuticals Inc.

Net Margins Return on Equity Return on Assets
Osmotica Pharmaceuticals plc -2.33% 0% 0%
Rocket Pharmaceuticals Inc. 0.00% -46.8% -32.5%

Liquidity

Osmotica Pharmaceuticals plc’s Current Ratio is 1.3 while its Quick Ratio is 1.1. On the competitive side is, Rocket Pharmaceuticals Inc. which has a 12.5 Current Ratio and a 12.5 Quick Ratio. Rocket Pharmaceuticals Inc. is better positioned to pay off short and long-term obligations compared to Osmotica Pharmaceuticals plc.

Institutional & Insider Ownership

Roughly 37% of Osmotica Pharmaceuticals plc shares are held by institutional investors while 84.1% of Rocket Pharmaceuticals Inc. are owned by institutional investors. 41.8% are Osmotica Pharmaceuticals plc’s share held by insiders. Competitively, insiders own roughly 5.7% of Rocket Pharmaceuticals Inc.’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Osmotica Pharmaceuticals plc -0.38% -11% 0% 0% 0% -3.68%
Rocket Pharmaceuticals Inc. -13.1% -24.08% -42.9% -33.59% 41.13% 34.1%

For the past year Osmotica Pharmaceuticals plc had bearish trend while Rocket Pharmaceuticals Inc. had bullish trend.

Summary

Osmotica Pharmaceuticals plc beats on 6 of the 9 factors Rocket Pharmaceuticals Inc.

Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. The company's promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER to treat Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone to treat muscle spasms; and ConZip for pain, as well as women's health products, including Divigel for menopause; and OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods. Its non-promoted approved products comprise Methylphenidate ER for ADHD; Venlafaxine ER tablets for major depressive disorder and social anxiety disorder; Hydromorphone ER for pain; Nifedipine ER for hypertension; Sodium Benzoate/Sodium Phenylacetate for hyperammonemia; Oxybutynin ER for overactive bladder; and prescription prenatal vitamins for nutritional requirements during pregnancy. The company's products under development include Ontinua ER, which is in Phase III clinical trials to treat multiple sclerosis spasticity, and Phase I clinical trials to treat opioid and alcohol use disorders; RVL-1201, which is in Phase III clinical trials to treat Blepharoptosis; and Osmodex and other ANDAs for various indications. Osmotica Pharmaceuticals plc is based in Bridgewater, New Jersey.

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has two lentiviral vector (LVV) programs under clinical testing to treat fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells; and three LVV programs for the treatment of other rare genetic diseases, as well as an adeno-associated viral vector program, which is under preclinical development. The company has collaboration agreements with Lund University, Sweden; and Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas. The company is headquartered in New York, New York.